• Adaptive radiotherapy
    • In-room imaging
    • Prostate
    • Pancreas
    • Brain tumors
    • Breast cancer
    • Gynecological
    • Head & neck cancer
    • Kidney cancer
    • Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Elekta Versa HD® Elekta Versa HD®
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
      • Quality Assurance
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell GammaPlan
    • Oncology Software
      • Elekta ONE
        • Oncology care
        • Smart Workflows
        • Treatment Applications
        • Real-world outcomes
        • Subscribe to Better
        • Elekta Axis Cloud
        • Interoperability
        • Professional Services
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
        • Xoft Xoft
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectal
        • Bladder
        • Cervix
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
    • Veterinary Radiation Therapy
    • Life Sciences
      • Elekta Kaiku
    • Elekta Care
    • Elekta Care Support Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Committee
        • Integrity Line
        • Programs
        • Risk management
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Committee
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • Market and Trends
                  • The share
                    • Financials
                      • Funding
                        • Reports & presentations
                        • Press releases
                        • IR calendar
                        • IR contacts
                    • Newsroom
                      • Newsroom
                        • Press Releases
                        • FOCUS Magazine
                        • Videos
                        • Image bank
                    • Careers at Elekta
                      • Jobs
                  ENSV
                  Login
                  • Products
                    • Radiation Therapy
                      • Treatment Delivery
                        • Elekta Unity
                        • Elekta Versa HD®
                        • Elekta Harmony
                        • Elekta Infinity
                      • Quality Assurance
                    • Stereotactic Radiosurgery
                      • Delivery
                        • Elekta Esprit
                      • Treatment Planning
                        • Leksell GammaPlan
                      • Versa HD
                    • Oncology Software
                      • Elekta ONE
                        • Oncology care
                        • Smart Workflows
                        • Treatment Applications
                        • Real-world outcomes
                        • Subscribe to Better
                        • Elekta Axis Cloud
                        • Interoperability
                        • Professional Services
                    • Brachytherapy
                      • Elekta Studio
                      • ImagingRing
                      • Venezia
                      • Flexitron
                      • Geneva
                      • Head and Neck
                      • Bronchus and Oesophagus
                      • Xoft
                      • Breast
                      • Skin
                      • Prostate
                      • Rectal
                      • Bladder
                      • Cervix
                      • Oncentra Brachy
                    • Neurosurgery
                      • Leksell Vantage Stereotactic System
                    • Veterinary Radiation Therapy
                    • Life Sciences
                      • Elekta Kaiku
                  • Services
                    • Elekta Care
                    • Elekta Care Support Services
                    • Elekta Care 360
                    • Elekta Care Learning
                    • Elekta Care Community
                    • Elekta Partner Community
                  • Patients
                    • MR-Linac Treatment
                    • Brachytherapy Treatment
                    • Gamma Knife Treatment
                    • Radiation Therapy Treatment
                    • Treatment Centers
                  • Company
                    • Partnering with Elekta
                    • About us
                      • Board of Directors
                      • Code of Conduct
                      • Corporate Citizenship
                      • Executive Committee
                      • Integrity Line
                      • Programs
                      • Risk management
                      • Story
                    • Sustainability
                    • Corporate Governance
                      • Shareholders’ meetings
                        • Board of Directors
                          • Executive Committee
                            • Auditors
                            • Reports
                          • Investors
                            • Investment case
                              • Outlook
                              • Market and Trends
                                • The share
                                  • Financials
                                    • Funding
                                      • Reports & presentations
                                      • Press releases
                                      • IR calendar
                                      • IR contacts
                                    • Newsroom
                                      • Press Releases
                                      • FOCUS Magazine
                                      • Videos
                                      • Image bank
                                    • Careers at Elekta
                                      • Jobs
                                  • Contact
                                  • Medical Affairs
                                  • Regulatory Affairs
                                  • Suppliers
                                    • About Elekta Procurement
                                    • Sustainable Sourcing
                                    • Performance Management
                                      • Production Part Approval Process
                                      • Supplier Escalation Form
                                      • Non Conformance Management
                                      • Supplier Performance Management
                                      • Obsolescence Management
                                    • Compliance Management
                                    • Invoicing Process
                                    • Elekta T&C
                                    • Documents & Training
                                    • Our Global Presence
                                  • Standard of care
                                    • Adaptive radiotherapy
                                    • In-room imaging
                                    • Prostate
                                    • Pancreas
                                    • Brain tumors
                                    • Breast cancer
                                    • Gynecological
                                    • Head & neck cancer
                                    • Kidney cancer

                                  Year-end report May–April 2025/26

                                  May 28, 2026

                                  Fourth quarter

                                  • In constant exchange rates, net sales decreased by 1 percent mainly driven by APAC, despite growth in China. Reported sales in SEK decreased by 8 percent amounting to SEK 4,762 M (5,156).
                                  • Fourth quarter was impacted by items affecting comparability of SEK 1,363 M (1,040) primarily related to a non-cash impairment of intangible and tangible assets of SEK 1,096 M (1,064).
                                  • Adjusted gross margin of 39.9 percent (40.3) negatively impacted by changes in foreign exchange rates while price increases and product launches contributed positively.
                                  • Adjusted EBIT amounted to SEK 902 M (843), corresponding to a margin of 18.9 percent (16.3). The increase is mainly related to the change of operating model. Higher amortization and lower capitalization had negative impact of around 220 basis points YoY.
                                  • Net income was SEK -863 M (-381) and EPS was SEK -2.27 (-1.01) before dilution and SEK -2.26 (-1.01) after dilution.
                                  • Cash flow after continuous investments declined to SEK 1,141 M (1,248). Severance payments of SEK approximately 160 M.


                                  Full year 2025/26

                                  • In constant exchange rates, net sales increased by 1 percent. Reported sales in SEK decreased by 7 percent amounting to SEK 16,718 M (18,016).
                                  • Book-to-bill ratio of 1.04 (1.09) reflecting lower business activity in emerging markets compensated by positive impact from product launches in Europe and growth in China.
                                  • 2025/26 was impacted by items affecting comparability of SEK 1,817 M (1,207), primarily impairment of intangible assets and restructuring charges related to the change of operating model.
                                  • Improved adjusted gross margin of 38.4 percent (37.8) supported by price increases.
                                  • Adjusted EBIT amounted to SEK 2,051 M (2,097), corresponding to a margin of 12.3 percent (11.6). EBIT margin adjusted for capitalization and amortization (EBITC) improved to 11.2 percent (8.6).
                                  • Net income was SEK -517 M (240) impacted by impairment and the restructuring charge. EPS was SEK -1.36 (0.62).
                                  • Cash flow after continuous investments of SEK 1,392 M (1,056). The strongest in 5 years, in spite of severance payments of approximately SEK 300 M.
                                  • For the fiscal year 2026/27, net sales in constant currency is expected to increase YoY, with an improvement in the EBIT margin.
                                  • The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two instalments) for FY 2025/26.
                                  Group summaryQ4
                                  Full year

                                  SEK M2025/262024/25Δ 2025/262024/25Δ 
                                  Book-to-bill0.961.12-15% 1.041.09-5% 
                                  Net sales4,7625,156-8% 16,71818,016-7% 
                                  Net sales in constant exchange rates   -1%1  1%1
                                  Adjusted gross margin 239.9%40.3%-0.3 ppts 38.4%37.8%0.6 ppts 
                                  Adjusted EBITDA 31,2061,1654% 3,3003,396-3% 
                                  Adjusted EBITDA margin 325.3%22.6%2.7 ppts 19.7%18.8%0.9 ppts 
                                  Adjusted EBIT 49028437% 2,0512,097-2% 
                                  Adjusted EBIT margin 418.9%16.3%2.6 ppts 12.3%11.6%0.6 ppts 
                                  Adjusted EBITC margin 518.9%14.3%4.6 ppts 11.2%8.6%2.6 ppts 
                                  Gross margin39.5%39.8%-0.3 ppts 37.4%37.4%-0.1 ppts 
                                  EBITDA9401,189-21% 2,5793,283-21% 
                                  EBITDA margin19.7%23.1%-3.3 ppts 15.4%18.2%-2.8 ppts 
                                  EBIT-461-197-134% 234890-74% 
                                  EBIT margin-9.7%-3.8%-5.9 ppts 1.4%4.9%-3.5 ppts 
                                  Net income-863-381-127% -517240-315% 
                                  Cash flow after continuous investments1,1411,248-107 1,3921,056336 
                                  Adjusted earnings per share before/after dilution, SEK 60.57 / 0.571.11 / 1.11-48% 2.43 / 2.433.08 / 3.08-21% 
                                  Earnings per share before/after dilution, SEK -2.27 / -2.26-1.01 / -1.01-124% -1.36 / -1.360.62 / 0.62-319% 

                                  1 Compared to last fiscal year based on constant exchange rates.
                                  2 Adj. gross margin = Gross margin excluding items affecting comparability, page 28.
                                  3 Adj. EBITDA = EBITDA excluding items affecting comparability, page 29.
                                  4 Adj. EBIT = Operating income (EBIT) excluding items affecting comparability, page 29.
                                  5 Adj. EBITC margin = EBIT adjusted for R&D capitalization and amortization, excluding items affecting comparability, page 31.
                                  6 Adj. earnings per share = Net income excluding items affecting comparability, attributable to Parent Company shareholders, in relation to the weighted average number of shares (excl. treasury shares), page 30.

                                  Strong improvement in profitability for the fourth quarter and full year
                                  Net sales for the full year 2025/26 increased by 1 percent in constant exchange rates. Actions to reset Elekta’s operating model were completed in Q4, with annualized cost savings exceeding SEK 500 M and serving as the driver behind the improvement of the Q4 adjusted EBIT margin from 16.3 to 18.9 percent. The fourth quarter was impacted by items affecting comparability of SEK 1,363 M, with no impact on cash flow. Net debt decreased to SEK 3,191 M.

                                  Result development
                                  Net sales in Q4, in constant exchange rates, decreased by 1 percent year over year, primarily due to lower sales in APAC despite growth in China. For the full year 2025/26, however, net sales in constant exchange rates increased by 1 percent, driven mainly by growth in EMEA. The weaker book-to-bill ratio in the fourth quarter reflected lower business activity in emerging markets, particularly in Middle East and Southeast Asia. In addition, stricter order acceptance criteria contributed to a more selective approach to recognizing new orders. While these measures temporarily affected the book-to-bill ratio, they also reflect a more disciplined strategy focused on improving our order quality and with no impact on our growth ambition.
                                   
                                  Since September last year, our primary focus has been on resetting and stabilizing the company. This is a strong foundation for our ambitions to further improve profitability and to create the right basis for driving focused innovation and growth going forward. The Group delivered a strong improvement in profitability for the full year, with the adjusted gross margin for the year increasing to 38.4 percent (37.8), reflecting the positive contribution from product launches and improved pricing. In the fourth quarter, however, adjusted gross margin declined slightly to 39.9 percent (40.3), as the benefits from pricing and new products were offset by the negative effects of currencies. Adjusted EBIT margin for the full year improved to 12.3 percent (11.6). The full-year adjusted EBITC margin improved to 11.2 percent (8.6), the highest level in five years. Profitability improved further in the fourth quarter, with adjusted EBIT margin increasing to 18.9 percent (16.3). The strong quarter was primarily driven by cost savings associated with the implementation of the new operating model.
                                   
                                  Operating cash flow after continuous investments improved by SEK 336 M to SEK 1,392 M for the full year, representing the strongest cash flow in five years. The Board proposes a dividend of SEK 2.40 (2.40) per share, corresponding to a total of SEK 917 M, reflecting Elekta’s solid financial position.
                                   
                                  Actions taken to improve quality of earnings
                                  Through the execution of our first Must-Win Battle, we now have implemented a new operating model designed to simplify the organization, increase agility, and drive decision-making closer to the business. As part of these efforts, we have reduced the workforce by more than 500 employees, resulting in annualized cost savings exceeding SEK 500 M. A significant share of these savings was already realized during the fourth quarter, positively impacting profitability.
                                   
                                  During the quarter, items affecting comparability of a total of SEK 1,363 M (1,040) were recognized, with no impact on cash flow. Following the implementation of a more focused and commercially driven product development roadmap, capitalized development costs amounting to SEK 851 M were impaired. As a result of impairments of goodwill related to discontinued products and other balance sheet-related items, a further IAC of SEK 519 million was recognized during the quarter. The adjustments reflect a reassessment to better align the balance sheet with current business assumptions and improves Elekta’s ability to execute on its future strategy.
                                   
                                  Outlook
                                  Looking at the fiscal year 2026/27, we expect net sales in constant currency to increase year over year, with an improvement in the EBIT margin. On our Capital Markets Day on June 17, we will present our mid-term financial targets ending at full year 2028/29.

                                  Jakob Just-Bomholt
                                  President and CEO

                                  This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-28 07:30 CEST.

                                  Attachments


                                  Elekta Q4 Report 2025 2026 ENG

                                  Downloads

                                  • Elekta Q4 Report 2025 2026 ENG
                                  • Products
                                    • Radiation Therapy
                                    • Stereotactic Radiosurgery
                                    • Oncology Software
                                    • Brachytherapy
                                    • Neurosurgery
                                    • Veterinary Radiation Therapy
                                    • Life Sciences
                                  • Services
                                    • Elekta Care
                                    • Elekta Care Support Services
                                    • Elekta Care 360
                                    • Elekta Care Learning
                                    • Elekta Care Community
                                    • Elekta Partner Community
                                  • Patients
                                    • MR-Linac Treatment
                                    • Brachytherapy Treatment
                                    • Gamma Knife Treatment
                                    • Radiation Therapy Treatment
                                    • Treatment Centers
                                  • Company
                                    • Partnering with Elekta
                                    • About us
                                    • Sustainability
                                    • Corporate Governance
                                    • Investors
                                    • Newsroom
                                    • Careers at Elekta
                                    • Digital Product Security
                                    • Offices
                                    • Regional pages
                                  • ©2026 Elekta
                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                                  © 2026 Elekta

                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.